SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-22-000078
Filing Date
2022-05-05
Accepted
2022-05-05 16:05:15
Documents
60
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20220331.htm   iXBRL 10-Q 1630608
2 EX-31.1 exhibit311q12022.htm EX-31.1 9993
3 EX-31.2 exhibit312q12022.htm EX-31.2 10013
4 EX-32.1 exhibit321q12022.htm EX-32.1 5652
5 EX-32.2 exhibit322q12022.htm EX-32.2 5781
  Complete submission text file 0001714899-22-000078.txt   6268656

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20220331.xsd EX-101.SCH 39178
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20220331_cal.xml EX-101.CAL 53969
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20220331_def.xml EX-101.DEF 179798
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20220331_lab.xml EX-101.LAB 492761
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20220331_pre.xml EX-101.PRE 326459
54 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20220331_htm.xml XML 984579
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 22896127
SIC: 2836 Biological Products, (No Diagnostic Substances)